A recent preclinical study of mouse models revealed that increased TGFβ activity in liver metastasis of CRC drives immunotherapy resistance by inducing T cell exclusion in the tumor microenvironment [26]. This evidence concerns the gene TGFB1 and colorectal carcinoma.